Explore Allbiosyn
Years
Milligrams to hundreds of kilograms large-scale production capacity of nucleotide raw materials
An innovation benchmark in the global nucleic acid drug raw materials field
Allbiosyn Biotechnology Co., Ltd. is a rapidly growing biotechnology enterprise specializing in the R&D and production of nucleotide raw materials. Leveraging our proprietary end-to-end innovation platform spanning nucleic acid drug development and manufacturing, we have successfully developed multiple modified nucleosides and functional nucleic acid molecules with independent intellectual property rights.
More
·
Oligonucleotide Synthesis Raw Materials
·
Gene Sequencing And In Vitro Diagnostic Reagents
·
mRNA Vaccine Raw Materials
·
Dye
·
New Series
Explore Allbiosyn products
Allbiosyn is always committed to providing cost-effective and innovative nucleotide raw materials
01
Oligonucleotide Synthesis Raw Materials
| Nucleosides | Modified Nucleosides |
| Protected Nucleosides(PNS) | Phosphoramidites |
| Succinates | Delivery System |
Explore Allbiosyn Services
Allbiosyn Team
Blog
Allbiosyn Debuts at CPHI Shanghai 2025
Allbiosyn made its exhibition debut at CPHI Shanghai 2025, presenting novel nucleic acid raw materials including high-purity modified nucleosides, phosphoramidites, and customized nucleotide modifiers.
2025-09-23
Allbiosyn Showcases Innovative Nucleic Acid Solutions at CPHI Shenzhen 2025
Allbiosyn recently exhibited at CPHI Shenzhen, strengthening its presence as a leading provider of nucleic acid raw materials and synthesis technologies. The event provided an ideal platform to connect with key players in the pharmaceutical and biotech industries.
2025-09-23
On March 15, 2025, the three-day 2025 E-Trade Bio-industry Conference (BIOCHINA) successfully concluded at Suzhou International Expo Center. This conference, themed "Innovation Without Borders, Collaborative Coexistence," gathered 850 top global speakers and 30,000 professional attendees, covering 50,000㎡ of exhibition space, comprehensively showcasing cutting-edge technologies and industrial potential in the biomedical field. As a leader in the nucleic acid raw material sector, Allbiosyn Bio showcased its core product matrix at the exhibition, to jointly explore the future of nucleic acid drug industrialization with global partners.
2025-03-18
2025-03-18
Imetelstat is the world's first approved telomerase inhibitor drug, developed by Geron Corporation in the United States, and approved by the FDA on June 6, 2024 (trade name Rytelo®), for the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia.
2025-03-04
2025-03-04
Join email subscription
You will receive Allbiosyn's latest product information and recent updates
Wish to receive more updates from Allbiosyn
Stay up-to-date with the latest product releases, technology trends, and upcoming events.
- All
- Product Management
- News Information
- Introduction Content
- Enterprise Outlets
- FAQ
- Corporate Video
- Corporate Album
Phone:+8618666985712
Email:info@allbiosyn.com
WeChat ID: 18666985712
Add: Building 1, 883-1885 Pinggang Road, Lingang District,Shanghai,China.
Copyright © 2025 Allbiosyn Biotechnology Co., Ltd. All Rights Reserved.